|
| 37085425 | Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel. | Eur Urol | 2024 |
| 36256912 | Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984. | J Clin Oncol | 2023 |
| 37526936 | Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG 1216 Phase 3 Trial. | JAMA Netw Open | 2023 |
| 37524096 | Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial. | Lancet | 2023 |
| 37799388 | Use of recombinant microRNAs as antimetabolites to inhibit human non-small cell lung cancer. | Acta Pharm Sin B | 2023 |
| 37289025 | The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer. | Cancer Res | 2023 |
| 37285550 | Crisis of the Clinical Trials Staff Attrition After the COVID-19 Pandemic. | JCO Oncol Pract | 2023 |
| 36604210 | ATR Inhibition in Advanced Urothelial Carcinoma. | Clin Genitourin Cancer | 2023 |
| 36596844 | Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer. | Oncogene | 2023 |
| 35984996 | EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma. | J Clin Oncol | 2023 |
| 34991070 | Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2022 |
| 35446628 | Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216). | J Clin Oncol | 2022 |
| 36497466 | The Impact of Facility Surgical Caseload Volumes on Survival Outcomes in Patients Undergoing Radical Cystectomy. | Cancers (Basel) | 2022 |
| 36726555 | Immune Checkpoint Inhibitors in the Pre-operative Setting and Impact on the Primary Renal Tumor. | Kidney Cancer | 2022 |
| 35875145 | A Cancer Health Needs Assessment Reveals Important Differences Between US-Born and Foreign-Born Latinos in California. | Front Oncol | 2022 |
| 36212798 | Evaluating the Optimal Duration of Immunotherapy in Kidney Cancer. | Kidney Cancer | 2022 |
| 36109521 | Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity. | Nat Commun | 2022 |
| 36069866 | A Genomically and Clinically Annotated Patient-Derived Xenograft Resource for Preclinical Research in Non-Small Cell Lung Cancer. | Cancer Res | 2022 |
| 36251389 | The 5-Hydroxymethylcytosine Landscape of Prostate Cancer. | Cancer Res | 2022 |
| 35131040 | Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. | Lancet Oncol | 2022 |
| 35031545 | Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy. | Clin Cancer Res | 2022 |
| 33409898 | Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879. | Invest New Drugs | 2021 |
| 33829609 | Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR). | Oncologist | 2021 |
| 33737681 | Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer. | Sci Rep | 2021 |
| 33592176 | A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. | Lancet | 2021 |
| 33754032 | <i>In vivo</i> fermentation production of humanized noncoding RNAs carrying payload miRNAs for targeted anticancer therapy. | Theranostics | 2021 |
| 33583720 | Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G. | Clin Lung Cancer | 2021 |
| 33500355 | Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216). | Clin Cancer Res | 2021 |
| 34436521 | Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial. | JAMA Oncol | 2021 |
| 34632170 | Defining the Optimal Management Strategy for Small Renal Masses. | Kidney Cancer | 2021 |
| 34036220 | Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung Cancer. | JCO Precis Oncol | 2021 |
| 33974442 | Prognostic Factors in De Novo Metastatic Renal Cell Carcinoma: A Report From the Latin American Renal Cancer Group. | JCO Glob Oncol | 2021 |
| 33229301 | Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design. | Clin Lung Cancer | 2021 |
| 33262136 | Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer. | Clin Cancer Res | 2021 |
| 32315455 | Germline and somatic DNA repair gene alterations in prostate cancer. | Cancer | 2020 |
| 31951493 | Framing Pragmatic Strategies to Reduce Mortality From Bladder Cancer: An Endorsement From the Society of Urologic Oncology. | J Clin Oncol | 2020 |
| 32915679 | Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. | J Clin Oncol | 2020 |
| 32624423 | Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer. | Urol Oncol | 2020 |
| 32903788 | Pan-Cancer Analysis of <i>BRCA1</i> and <i>BRCA2</i> Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity. | JCO Precis Oncol | 2020 |
| 32727885 | Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer. | Clin Cancer Res | 2020 |
| 32446863 | Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [European Urology 77 (2020) 223-250]. | Eur Urol | 2020 |
| 32239988 | Current Approaches to the Treatment of Advanced or Metastatic Renal Cell Carcinoma. | Am Soc Clin Oncol Educ Book | 2020 |
| 30528315 | Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non-small-cell Lung Carcinoma. | Clin Lung Cancer | 2019 |
| 31763512 | Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249). | Kidney Cancer | 2019 |
| 31473089 | Immunohistochemical expression of renin is a prognostic factor for recurrence in nonmetastatic renal cell carcinoma. | Urol Oncol | 2019 |
| 31604910 | RORγ is a targetable master regulator of cholesterol biosynthesis in a cancer subtype. | Nat Commun | 2019 |
| 31375453 | A Population-Based Study of Incidence and Survival of 1588 Thymic Malignancies: Results From the California Cancer Registry. | Clin Lung Cancer | 2019 |
| 31398279 | Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy. | Cancer | 2019 |
| 31195180 | SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). | J Thorac Oncol | 2019 |
| 31446228 | An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer. | Lung Cancer | 2019 |